Introduction: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of lung adenocarcinoma. However, approximately 5% to 10% of patients with lung adenocarcinoma with EGFR sensitive mutations have primary resistance to EGFR TKI treatment. The underlying mechanism is unknown.
Methods: This study used next-generation sequencing to explore the mechanisms of primary resistance by analyzing 11 patients with primary resistance and 11 patients sensitive to EGFR TKIs. Next-generation targeted sequencing was performed on the Illumina X platform for 483 cancerrelated genes. EGFR mutation was initially detected using the amplification refractory mutation system.
Results: Potential primary resistance mechanisms were revealed by mutations unique to the EGFR TKI resistance group. Among the 11 resistant patients, 45% (five of 11) harbored a known resistance mechanism, such as MNNG HOS Transforming gene (MET) amplification de novo T790M mutation or overlapping T790M and phosphatase and tensin homolog gene (PTEN) loss and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) amplification. In six of 11 resistant cases (54%), potential novel mutations that might lead to drug resistance were identified (including transforming growth factor beta receptor 1 gene [TGFBR1] mutation and/or EGFR structural rearrangement mechanistic target of rapamycin kinase gene [MTOR] mutation, transmembrane protease, serine 2 gene [TMPRSS2] fusion gene, and v-myc avian myelocytomatosis viral oncogene homolog gene [MYC] amplification). By analyzing somatic mutation patterns, the frequency of C:G/T:A transitions in the patients with primary resistance was significantly higher than that in sensitive group and occurred more frequently in the non-CpG region (Cp(A/C/T)/T).
Introduction
Lung cancers harboring mutations sensitive to EGFR demonstrate good objective responses for treatment with EGFR tyrosine kinase inhibitors (TKIs). However, according to previous clinical trials, [1] [2] [3] approximately 5% to 10% of patients with lung adenocarcinoma with EGFR sensitive mutations have primary resistance to treatment with EGFR TKIs. Meanwhile, for EGFR TKI-sensitive patients, secondary resistance due to drug resistance invariably emerges during treatments after 8 to 16 months of treatment. [1] [2] [3] Currently, some mechanisms of acquired resistance to EGFR TKIs have been revealed, including T790M mutation, 4 MNNG HOS Transforming gene (MET) amplification, 5 or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation. 6 New drugs targeting these mechanisms, such as osimertinib, 7 have been developed to overcome secondary resistance to EGFR TKIs. However, little is known about the molecular background of primary resistance. Primary resistance to EGFR TKIs is defined as resistance in patients with EGFR sensitive mutant adenocarcinoma who have disease progression in fewer than 90 days (3 months) without any evidence of objective response while receiving EGFR TKIs. 8 Thus, primary resistance has become the main problem of EGFR TKI treatment.
Several studies have shown that primary resistance to EGFR TKIs is associated with KRAS mutations and ALK receptor tyrosine kinase gene (ALK) rearrangement. However, coexistence of EGFR and KRAS mutations occurs in less than 1% of patients with lung cancer, 9 and EGFR mutations coexist with ALK rearrangement in less than 2% of lung adenocarcinoma. 10 The acquired resistancerelated molecular mutations such as T790M and MET amplification could also exist in pretreatment tissues and contribute to primary resistance to EGFR TKIs. 5, 11, 12 However, these mechanisms cannot explain all cases of primary resistance in clinical practice. Recently, several preclinical and retrospective studies demonstrated that BCL-2 like 11gene (BIM) deletion polymorphisms, a germline mutation, could predict poor response to EGFR TKI treatment. 13, 14 But whether BIM deletion can predict primary resistance to EGFR TKIs is controversial: several studies did not find any difference between BIM deletion or wild-type patients in EGFR TKI treatment. 15, 16 The underlying molecular mechanisms of primary resistance to treatment with EGFR TKIs are not fully elucidated. Therefore, we conducted this exploratory study to identify novel potential mechanisms of primary resistance to EGFR TKIs by next-generation sequencing (NGS).
Materials and Methods

Ethics Statement
This study was approved by the ethics committee of Peking University Cancer Hospital. All patients signed informed consent for use of their tumor tissue and blood samples.
Sample Collection and DNA Extraction
For most patients, formalin-fixed, paraffin-embedded materials were used in this study; the exception was one patient (Tumor ID TSCR-T) who could provide primary tumor tissue samples collected during surgery and frozen immediately in liquid nitrogen. A 5-mm section of a hematoxylin and eosin-stained slide was reviewed by a pathologist to evaluate tumor purity and circle the tumor area. For some patients, white blood cells from blood samples were available for somatic variant calling.
Genomic DNA was extracted from tumor tissue and blood samples by using TIANamp Genomic DNA Kit (Tiangen, Beijing, People's Republic of China). The quality of purified DNA samples was examined by three methods: agarose gel electrophoresis to analyze the degree of DNA degradation, Nanodrop (Thermo Fisher Scientific, Waltham, MA) analysis of OD260/280 for DNA purity, and Qubit 2.0 fluorometric quantitation (Life Technologies, Carlsbad, CA) to detect DNA concentration.
Library Construction, Hybridization, and Sequencing
Genome DNA was randomly sheared into 150-to 300-base pair segments with a Covaris S220 Focused Ultrasonicator (Covaris, Woburn, MA). After end repair and dA-tailing, indexed adaptors were ligated to DNA fragments to perform precapture polymerase chain reaction (PCR).
We adapted a customized 483-gene panel based on the Agilent liquid-phase hybrid capturing system for target enrichment (Agilent Technologies, Waldbronn, Germany). This panel was designed to target a total of 483 cancer-related human protein-coding genes; intron regions of 19 genes; and three single-nucleotide polymorphism sites, namely, C8orf34, UGT1A9, and UGT1A1. The coverage of exon regions and intron regions was greater than 99.9%. Exon region and three singlenucleotide polymorphism sites were detected, and the intron region of 19 genes were detected for gene fusion events. The total length of both exon and intro regions was about 2.3 megabase pairs. Manufacturer recommendations were followed during the liquid-phase hybridization step.
After library enrichment, postcapture PCR was performed to yield final sequencing libraries. The fragment size of the prepared library was qualified using a 2100 Bioanalyzer (Agilent Technologies), and library concentration was quantified using a quantitative PCR NGS library quantification kit (Agilent Technologies). Multiplexed libraries were sequenced at the Novogene sequencing facility using the HiSeq platform (Illumina, San Diego, CA).
QC and Sequence Alignment
Quality control (QC) was conducted to filter out adaptor sequences and low-quality reads. The base quality over or equal to 20 and 30 of all samples were greater than 90% and 85%, respectively. The sequencing reads were aligned to the hg19 human reference genome using the Burrows-Wheeler transform in the program BWA (0.6.2-r126) 17 with default parameters. Duplications were removed using Picard (http://picard. sourceforge.net). In this study, all samples had coverage of the target region greater than 99% and the mapping rate was at least 95%. The effective depth of most samples was higher than 200Â, and the average effective depth was 491.6Â.
Variant Calling
Somatic single-nucleotide variants (SNVs) were called using MuTect (v1.1.5), 18 and somatic InDels were called using strelka. 19 Somatic mutations were filtered at several thresholds, including a read depth greater than 50Â, with no fewer than five reads containing the alternate allele. Structural variation events were identified with in-house software, and fusion events were retained only if they were supported by more than four split reads on two genes. Function annotations were made with ANNOVAR, 20 COSMIC, 21 and the ClinVar database. Enrichment using the Kyoto Encyclopedia of Genes and Genomes was performed with the DAVID online server. 22 To analyze mutation signatures, germline mutations were called by MuTect.
The copy number of genes was analyzed by ExomeCNV, 23 with the circular binary segmentation algorithm. A control set for somatic copy number variation was generated from white blood cell samples from some patients. For patients with tumor samples that lacked white blood cell samples, a precalculated control set from multiple white blood cell samples was used. In the final report, we kept only copy number variation events of six drug-related genes with copy numbers of at least 2.7: EGFR, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), MET, v-myc avian myelocytomatosis viral oncogene homolog gene (MYC), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 2 (FGFR2).
Results
Patient Characteristics
A total of 415 patients with lung adenocarcinoma from Peking University Cancer Hospital were enrolled in the study. All patients harbored EGFR-activating mutations, and had a history of treatment with EGFR TKIs (including gefinib, erlotinib, or icotinib) between January 2006 and January 2015. All 415 patients harbored mutations known (on the basis of previous studies) to associate with EGFR TKI activity, including EGFR exon 19 deletion, exon 21 L858R, exon 18 G719X, and exon 21 L861Q. The median follow-up time for these patients was 22.3 months (range 3.1-65.5). Of 415 patients, 171 (41.2%) received EGFR TKIs as first-line treatment. At the last follow up, 22.4% of the patients (93 of 415) were still receiving EGFR TKI treatment. The median progression-free survival (PFS) was 8.5 months. Of the 415 patients, 84 (20.2%) exhibited primary resistance to EGFR TKI treatment. Of the resistant patients, 11 had sufficient tumor tissue for NGS analysis and met the filtering criteria to be included in this study. For comparison, another 11 EGFR TKI-sensitive patients (PFS >12months) meeting these standards were also included. The filtering criteria were as follows: (1) after DNA extraction, the DNA was tested by electrophoresis on a 1% agarose gel and the main band was at least 600 base pairs; (2) there was effective coverage with a mean sequencing depth greater than 200Â; (3) the absolute difference between mean depth and median depth of all bins of the 483-gene panel was less than 50; and (4) all the reads aligned to hg19, and the mapping rate was at least 95%. The baseline clinical characteristics, including age, sex, smoking status, EGFR mutation, and types of EGFR TKIs were well balanced between the sensitive group and the group with primary resistance (Supplementary Table 1 ).
Patients with Primary Resistance Showed Unique Somatic Variations
To explore possible mechanisms of primary resistance to EGFR TKI treatment, 11 patients with lung adenocarcinoma with primary resistance were included in the study; all resistant patients had archival EGFR TKI-naive tissues for NGS. For comparison, 11 EGFR TKI-sensitive samples were also sequenced. Eight of the 11 patients in each group had paired white blood cells available. Because several important mutations have a low alteration allele frequency, higher sequencing depth is required for mutation calling. Thus, we focused on the genome region of 483 cancer-associated genes by targeted NGS technology. Under strict QC, the extracted DNA was sequenced to high uniform coverage with a mean sequencing depth of 491.6Â. The mapping rate ranged from 98.41% to 99.77%, and the percent coverage of the target region was greater than 99.75% ( Supplementary Fig. 1 ).
The number of SNVs and insertion-deletions (InDels) differed from patient to patient. The respective average numbers of somatic SNVs and InDels were 9.75 and 2.625 for the sensitive group and 18.625 and 2 for the group with resistance. The differences in the numbers of SNVs/InDels between the two groups were not statistically significant (p ¼ 0.43 and 0.91) ( Supplementary Fig. 2 ). We also analyzed the allelic frequency of EGFR mutations in the two cohorts. The allelic frequency of EGFR exon 19 deletion was significantly higher in group with sensitivity (0.158 versus 0.059 [p ¼ 0.035]). The median allelic frequency of EGFR exon 21 L858R was also higher in the group with sensitivity, but the difference was not statistically significant (0.42 versus 0.22
To eliminate detection bias, we further analyzed somatic SNVs/InDels that were (1) detected in at least two pretreatment tissue specimens and (2) unique in the resistant group. These SNVs/InDels were defined as high-frequency somatic variations. Besides the common EGFR sensitive mutation and a high prevalence of mutations in tumor protein p53 gene [TP53], patients in the group with resistance contained the following three unique highly frequent SNVs/InDels: (1) 26 ( Fig. 1 ). Besides these three mutations, we also found that patient TG93348 had a mutation in transforming growth factor beta receptor 1 gene [TGFBR1] Glu223X Figure 1 . High-frequency somatic variations for the EGFR tyrosine kinase inhibitor-sensitive group and group with primary resistance. Each group has eight patients who provided paired white blood cell samples as a control. In the EGFR tyrosine kinase inhibitor-sensitive group, patient 3531-ca has two mutation sites in EGFR. One is an exon 19 deletion and the other is a synonymous mutation. A low-frequency EGFR exon 19 deletion was detected using the amplification refractory mutation system in patient 1363-ca was not found next-generation sequencing. TP53, tumor protein p53 gene; GRIN2A, glutamate ionotropic receptor NMDA type subunit 2A gene; PLK1, polo like kinase gene; RB1, retinoblastoma 1 gene; MTOR, mechanistic target of rapamycin kinase gene; RICTOR, RPTOR independent companion of MTOR complex 2 gene; AR, androgen receptor gene; DSCAM, DS cell adhesion molecule gene; RNF43, ring finger protein 43 gene.
and patient TG81531 (posttreatment sample) harbored a TGFBR1 Val1222fs mutation. The two TGFBR1 mutations were a frameshift deletion and a stop-gain mutation, respectively, which may relate to resistance to EGFR TKIs. Neurofibromin 1 gene (NF1) is reported to have predictive value for EGFR TKIs. 27 In this study, NF1 mutation existed uniquely in the group with primary resistance, but it occurred in only one patient's pretreatment tissue sample (NF1: NM_001042492: exon48: c.7175G>A: p.Gly2392Glu).
To reduce the bias that might have been caused by the small patient cohorts, we compared the six mutations identified in eight paired patients with resistance (RNF43, MTOR, RICTOR, DSCAM, TGFBR1, and NF1) with those in 33 patients with lung adenocarcinoma with EGFR mutation in The Cancer Genome Atlas by using a two-sided Fisher's exact test. 28 The occurrences of RNF43, MTOR, and RICTOR were significantly higher in the primary resistance group (Table 1) .
Patients in the resistant group were likely to have other mutations coexisting with EGFR sensitive mutations, including EGFR L858M (exon 21), L11F (exon 1), G719A (exon 18), and T790M (exon 20). Intragenic mutations in EGFR were considered a possible mechanism for TKI resistance; such mutations included T790M in exon 20, L747S in exon 19, and an insertion in exon 20. 29, 30 Four patients with uncommon mutations, including G719A, L858M, L11F, and L861Q, were found in this study. The first three coexisted with EGFR sensitive mutations, whereas the latter existed alone. Additionally, we found EGFR chromosome structural rearrangement in patient TG74187 and patient TG77905; both these patients belonged to the group with primary resistance to EGFR TKIs. No such chromosome structural rearrangement was found in the EGFR TKI-sensitive group (Supplementary Table 2) .
We also tried to detect fusion genes in both the sensitive and resistant groups. Transmembrane protease, serine 2 gene (TMPRSS2)-alkaline phosphatase, liver/ bone/kidney gene (ALPL) rearrangement was found in one patient with primary resistance. TMPRSS2-ERG, ETS transcription factor (ERG) fusion gene was reported with high prevalence in a prostate tumor and as a regulator of insulin-like growth factor-1 receptor (IGF1R). 31 No fusion gene was detected in the group sensitive to EGFR TKIs.
Copy number aberrations were also analyzed in the two cohorts. MET amplification and ERBB2 (HER2) copy number gain existed only in the group with primary resistance; phosphatase and tensin homolog gene (PTEN) loss was found in one patient in the resistant group. MYC amplification was found in two sensitive patients and one patient with primary resistance. MYC copy number gains in the patient with primary resistance (13.6-fold) were notably higher than in the sensitive patients (4.8-fold and 2.9-fold). EGFR amplification was found in both the sensitive group and the resistant group (Supplementary Table 3) .
BIM deletion polymorphism was detected in both groups. One patient in the sensitive group and one patient in the resistant group had the BIM deletion.
We inferred potential mechanism of primary resistance according to the high-frequency mutations unique in the group with primary resistance to EGFR TKIs. Among the 11 patients with primary resistance to EGFR TKIs, 45% (five of 11) harbored a known resistance mechanism (two patients had MET amplification, one patient had T790M mutation, one patient had coexisting T790M mutation and PTEN loss, and one patient had Her-2 amplification), whereas 54% (six of 11) harbored novel mutations that may lead to drug resistance (one patient had TGFBR1 mutation; one patient had EGFR structural rearrangement; one patient had EGFR structural rearrangement and TGFBR1 mutation in posttreatment tissue; one patient had MTOR mutation; one patient had TMPRSS2 fusion gene; and one patient had EGFR L861Q, MYC amplification, and BIM deletion). Three of 11 patients (27.3%) had multiple resistance mechanisms (Table 2) . Overall, these data suggest that the mechanism of primary resistance to EGFR TKIs is highly heterogeneous.
Signaling Pathways Possibly Related to Primary Resistance to EGFR TKIs
To further explore genetic differences between the two groups, genes unique to each group were analyzed with the pathway database in the Kyoto Encyclopedia of Genes and Genomes. Overall, we observed 20 and five pathways in the resistant and sensitive cohorts, respectively. Compared with the mutations in the sensitive samples, the mutations in the resistant samples were involved in more pathways (Fig. 2) . For the group with primary resistance to EGFR TKIs, the pathways included (1) EGFR and its downstream pathway, such as the Janus kinase/signal transducers and activators of transcription signaling pathway, ErbB signaling pathway, and mitogen-activated protein kinase (MAPK) signaling pathway; (2) pathways that relate to tumor cell function, such as cell cycle and focal adhesion; and (3) immune-related pathways, such as the T-cell receptor signaling pathway. These pathways were found in the resistant group only (Supplementary Table 4A) .
Pathways related to epithelial-mesenchymal transition (EMT) were found in both groups. These pathways include the transforming growth factor-b (TGF-b) signaling pathway in the sensitive group and the Wnt signaling pathway in both groups. However, the mutations in the Wnt pathway were not the same between the groups (Supplementary Tables 4A and B) .
Unique pathways in the resistant cohort included the ErbB pathway and its downstream MAPK and Janus kinase/signal transducers and activators of transcription signaling pathway; pathways related to cell functions, such as cell cycle and focal adhesion; and pathways associated with immune response (Fig. 2A) .
Single-Nucleotide Mutation Signature for the Group with Primary Resistance. For the somatic and germline mutation signature, patients in both groups showed similar patterns, either single-nucleotide changes, including A>T/T>A, A>C/T>G, A>G/T>C, C>A/G>T, C>T/G>A, and C>G/G>C (Supplementary Fig. 3A) or subdivided mutation patterns such as transversions, Fig. 3B and Supplementary Table 5) .
A/G, Cp(A/C/T)/T, (C/T)p*CpG/T, and (A/G) p*CpG/T (Supplementary
We examined the somatic mutation signature in more detail. For a limited number of somatic mutations in each sample, we pooled results of all samples in each group and compared the sum of the frequencies. We found that the most prevalent changes were C>T/G>A transitions and the frequency was higher in the group with primary resistance (51.3%) than in the sensitive group (43.6% [ Fig. 3A] ). This contrast between the resistant and sensitive groups indicates a possible influence of cytosine spontaneous deamination (C>T/G>A) on primary resistance to EGFR TKIs. For the subdivided five mutation patterns, we found that the frequency of transversions in the sensitive group was notably higher than that in the group with primary resistance (46.2% versus 32.0%). In addition, the C>T change in the non-CpG region (Cp(A/C/T)/T) occurred more frequently in the group with primary resistance than in the sensitive group (32.0% versus 15.4% [Fig. 3] ).
Considering the possible association of smoking status and C>T/G>A nucleotide transitions, we analyzed the smoking status of the two groups ( Table 2 ). The occurrence of C>T/G>A transition was not different between the smoking and the nonsmoking groups (p ¼ 0.55).
Dynamic Change in Samples before and after EGFR TKI Treatment. Of the 11 patients with primary resistance to EGFR TKIs, one provided both pre-and post-EGFR TKI treatment samples. This patient is a 56-yearold woman, who carried an EGFR 19 deletion in the adenocarcinoma. She experienced a PFS of 1.17 months after treatment with first-line gefitinib (a first-generation EGFR TKI). We made a target sequence of 483 cancerassociated genes from her paired samples. TGFBR1) and measured the frequency of these somatic mutations in the posttreatment sample from the same patient, who experienced primary resistance to gefitinib treatment. Eight of the nine mutations (the exception being IL7R) were also prevalent in the DNA of the posttreatment tumor. The WNK lysine deficient protein kinase 3 gene (WNK3) mutation emerged in the posttreatment sample (Fig. 4) . We further analyzed the nonsynonymous coding mutations and found increased allele frequencies of TP53, TGFBR1, and WNK3 and decreased allele frequencies of IL7R and EGFR. This patient underwent EGFR TKI treatment, so it is not surprising to find decreased frequency of EGFR. Notably, this patient with primary resistance also presented elevated frequencies of TGFBR1, a high-frequency somatic variation in the group with primary resistance. Taken together, our data showed that EGFR TKIs can also target EGFR sensitive mutations for patients with primary resistance to EGFR TKIs and that resistance mutations accumulate under the selection pressure of EGFR TKIs.
Discussion
Understanding of the mechanisms of primary resistance to EGFR TKIs in the patients with sensitive mutations is still extremely limited. Here, we utilized samples from two groups of patients with NSCLC harboring EGFR sensitive mutations that were sensitive to and demonstrated primary resistance to EGFR TKI treatment to investigate the potential mechanisms of resistance. Our data indicate that the mechanism of primary resistance to EGFR TKIs is highly heterogeneous. Using a genomewide analysis, we identified several genetic mechanisms related to primary resistance, including somatic mutations, signaling pathway alterations, and singlenucleotide mutation patterns. Our findings provide new insight into primary resistance to EGFR TKIs in the era of genotype-directed personalized treatment.
In the genomic analysis of 11 patients with primary resistance, molecular changes in EGFR and its downstream pathways are the most common. In the present study, two patients had T790M mutation along with EGFR sensitive mutations before treatment. T790M accounts for approximately 50% of acquired resistance. 6 T790M mutation can also initially coexist with EGFRactivating mutations, and patients with this mutation had shorter PFS in EGFR TKI treatment than did patients without it. 32 Several studies have indicated that a germline T790M mutation induces drug-free tumor progression. 33, 34 We have reason to regard the presence of T790M as a cause of primary resistance. Four uncommon mutations were found in this study, namely, G719A, L858M, L861Q, and L11F. The first three were sensitive mutations according to previous studies. 35, 36 The oncogenicity of L11F and its sensitivity to EGFR TKIs have not been fully elucidated. Because L11F is located in the extracellular region of EGFR, it is probably a neutral mutation. Uncommon mutations are associated with shorter PFS and lower objective response rates than are classical mutations (such as exon 19 deletion and exon 21 L858R). 36, 37 Prospective trials are needed to validate uncommon EGFR mutations as possible mechanisms of primary resistance. EGFR chromosome structural rearrangements were found only in the group with primary resistance. Although the function of this interesting exon skipping phenomenon is unknown, it has provided a new approach to study of mechanisms of primary resistance.
The allelic frequency of EGFR mutations in the sensitive group was higher than that in the group with primary resistance. Wu et al. 38 found the EGFR mutation abundance could predict benefit from EGFR TKI treatment for NSCLC. The potential heterogeneity might explain the underlying mechanism of primary resistance to EGFR TKIs.
In our study, mutations in EGFR downstream genes, including MET amplification, PTEN loss, and ERBB2 amplification, were associated with primary resistance to EGFR TKIs. Two of the 11 resistant patients had MET amplification. According to previous studies, activation of MET by hepatocyte growth factor has been well recognized as a secondary resistance mechanism to EGFR TKIs. 5 The prevalence of these genomic alternations in treatment-naive specimens with EGFR mutations is only 1.5%, 39 which is lower than the occurrence in patients in our study with primary resistance (two of 11 [18.2%] ). PTEN is a tumor suppressor gene that negatively regulates the PI3K/Akt/mTOR pathway 40 ; thus, the loss of PTEN 41 was also regarded as a mechanism for acquired resistance to EGFR TKIs. Our study found a single patient with PTEN loss that coexisted with EGFR sensitive mutations in the pretreatment tissue. A recent study found that 54.5% of patients (12 of 22) with primary resistance had loss of PTEN, suggesting the deletion of PTEN as a candidate for primary resistance. 42 One patient in this study had ERBB2 amplification. ERBB2 amplification 43 was also a potential mechanism of acquired resistance to EGFR inhibitors. Reduced expression of neurofibromin, the RAS guanosine triphosphatase-activating protein encoded by the NF1 gene, was related to erlotinib treatment. 27 In our study, one patient in the resistant group had NF1 mutation. Previous study has shown that low NF1 expression level is reported to be associated with primary resistance to EGFR TKIs. 27 However, whether NF1 mutation will result in low expression of NF1 is unknown. NF1 mutation is only a possible mechanism of primary resistance to EGFR TKIs. In a word, mutations in EGFR downstream genes enable the cancer cell to maintain its intracellular growth signaling pathways in the presence of EGFR TKIs. These somatic changes found in pretreatment tissue samples are possible mechanisms of primary resistance and suggest that the clonal selection of these genomic alternations during EGFR TKI treatment results in resistance to TKIs.
TGFBR1 mutation was a high-frequency mutation unique in the group with primary resistance to EGFR TKIs. Previous research indicated that activation of classical TGF-b signaling pathway was related to secondary resistance to EGFR TKIs in lung adenocarcinoma. 44 TGFBR1 is one of the receptors in the TGF-b pathway. Activation of the TGF-b pathway has been related to stem cells and EMT, 45, 46 which might cause resistance to EGFR TKIs. Stem cells and EMT are activated by either Smad-dependent pathways or Smadindependent pathways. 47, 48 Yamashita et al. reported that the TGFBR1 kinase activity is required in the activation of Smad-independent TGF-b pathways. 49 In our study, we also found a high frequency of mutations in mTOR and MAPK signaling pathways, which are also involved in Smad-independent pathways. This indicates that the mechanism of primary resistance might be the activation of Smad-independent TGF-b pathways through TGFBR1.
By analyzing somatic single-nucleotide mutation patterns, we found that the frequency of C>T/G>A transitions in the group with primary resistance was higher than that in sensitive group (43.6% versus 51.3%). This phenomenon indicated that cytosine spontaneous deamination C>T/G>A was positively associated with primary resistance to EGFR TKIs. 50 We found that germline variations in the group with primary resistance occurred more frequently in the non-CpG region (Cp(A/C/T)/T. According to the literature, a higher prevalence of C>T mutations is related to ultraviolet exposure 51 and C>T mutations have often been observed in cancer caused by tobacco smoking. 50 In our study, the C>T/G>A transition was enriched in the group with primary resistance but lacked correlation with smoking status (p ¼ 0.55). Our study is, to the best of our knowledge, the first time somatic singlenucleotide mutation patterns have been associated with primary resistance to EGFR TKIs, although validation by additional studies is needed.
We also found somatic mutations related to tumor cell function, such as cell cycle and cell adhesion. DSCAM is a high-frequency mutation in the resistant group. It is a member of the cell adhesion immunoglobulin superfamily. 26 MTOR and RICTOR, which are the components of a protein complex for cell cycle arrest and DNA damage, are also prevalent in the resistant group. 25 MYC (c-Myc) is a regulator gene that plays a role in cell cycle progression, apoptosis, and cellular transformation, 52 and its amplification in lung cancer was first reported in 1983. 53 Of note, MYC amplification in the group with primary resistance (13.6-fold) was significantly higher than that in the sensitive patients (4.8-and 2.9-fold). According to the literature, MYC amplification was regarded as an independent poor-prognostic factor for disease-free survival and overall survival in lung adenocarcinomas, 54, 55 and MYC inhibitors have recently been used in preclinical studies. Therefore, combination therapy with MYC inhibitors and EGFR TKIs seems to be a promising strategy for overcoming primary resistance to EGFR TKIs in lung cancer. Therapeutic impact was also considered in this study. One patient provided both pre-EGFR TKI treatment and post-EGFR TKI treatment samples. The increased allele frequencies of resistant mutations and decreased allele frequencies of sensitive mutations can be attributed to a preferential response of subclones of sensitive mutations in tumors with heterogeneous tumor cell populations. 56 Heterogeneity that derives from genetic differences and arises through clonal evolution may also be one of the explanations for resistance to EGFR TKIs.
Despite this interesting finding, our study has some limitations. First, this is a retrospective study in a single center, and additional prospective studies will be necessary to verify the results. Second, only 11 patients with primary resistance had enough available tissue and white blood cell samples for NGS; we have considered expanding the sample size for future studies. Finally, although possible mechanisms of primary resistance were examined in this study, molecular experiments will be required to confirm a definite relationship between these factors and primary resistance.
In summary, our study identified potential mechanisms of primary resistance for each patient in the group with primary resistance. Our data suggest that molecular mechanisms of primary resistance are highly heterogeneous. Of note, we are the first to demonstrate an association between single-nucleotide mutation patterns and primary resistance to EGFR TKIs. Further investigations with larger cohorts and experimental research are warranted to further explore these potential mechanisms. We believe that our study contributes to the understanding of primary resistance and the ongoing efforts to develop more personalized treatment.
